Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Fixed Sequence Crossover Study to Investigate the Effects of Carbamazepine on the Pharmacokinetics of Elinzanetant (BAY 3427080) in Healthy Participants.

NCT05028608 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05028608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05028608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Fixed Sequence Crossover Study to Investigate the Effects of Carbamazepine on the Pharmacokinetics of Elinzanetant (BAY 3427080) in Healthy Participants.
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
September 6, 2021
Completion date
January 20, 2022
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vasomotor symptoms as a sex hormone-dependent disorder in women and men